AG002UW4

27833-64-3 | 2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f][1,4]oxazepine succinate

AG002UW4

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	27833-64-3
Catalog Number	AG002UW4(AGN-PC-0JLA8S)
Chemical Name	2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f][1,4]oxazepine succinate
EC Number	248-682-0
IUPAC Name	butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
InChI	InChI=1S/C18H18ClN3O.C4H6O4/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18;5-3(6)1-2-4(7)8/h2-7,12H,8-11H2,1H3;1-2H2,(H,5,6)(H,7,8)
InChI Key	YQZBAXDVDZTKEQ-UHFFFAOYSA-N
MDL Number	MFCD00069298
Molecular Formula	C22H24ClN3O5
Molecular Weight	445.8961
NSC Number	759578
SMILES	CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2.OC(=O)CCC(=O)O
UNII	X59SG0MRYU
Synonyms	2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine, CL 71,563, CL-71,563, CL71,563, Cloxazepine, Hydrochloride, Loxapine, Loxapine, Loxapine Hydrochloride, Loxapine Monohydrochloride, Loxapine Succinate, Loxapinsuccinate, Loxipine Maleate, Loxipine Succinate, Loxitane, Maleate, Loxipine, Oxilapine, Succinate, Loxapine, Loxapine succinate, 27833-64-3, Loxapine succinate salt, Cloxazepin, Daxolin, Loxapac, Lederle, Loxapine (succinate), UNII-X59SG0MRYU, Loxapine,succinate, Loxapine, Succinate, CCRIS 1917, EINECS 248-682-0, X59SG0MRYU, CL 71563, CPD000058470, MLS000069383, MFCD00069298, NCGC00016160-02, SMR000058470, CAS-27833-64-3, 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate, 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine succinate (1:1), DSSTox_CID_25227, DSSTox_RID_80764, DSSTox_GSID_45227, Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1), C22H24ClN3O5, CL-71563, W-107092, CHEBI:6549, Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1), Succinic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1), Succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz(b,f)(1,4)oxazepine (1:1), SUM-3170, AZ-004, SR-01000002971, Loxapine succinate [USAN], Loxapine succinate [USAN:USP], Staccato-loxapine, butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine, Loxipine Succinate, Loxitane (TN), Prestwick_304, Lopac-L-106, AC1Q5VQU, Opera_ID_1518, Loxapine succinate (USP), SCHEMBL41643, MLS000758291, MLS001146961, MLS001401432, MLS002222201, SPECTRUM2300242, Loxapine succinate salt, solid, REGID_for_CID_71399, AC1L2G38, CHEMBL1201155, DTXSID3045227, CTK4G0318, AOB5330, ZX-AFC001324, HMS1568K06, HMS1922L14, HMS2051E05, HMS2093N20, HMS2095K06, HMS2232N05, HMS3262O21, HMS3374F02, HMS3393E05, HMS3652O10, HMS3712K06, Pharmakon1600-02300242, Tox21_110311, Tox21_500720, AZ-104, CCG-39497, HY-17390A, NSC759578, s4086, AKOS015994711, Tox21_110311_1, CS-4285, KS-1083, LP00720, NC00011, NSC-759578, VA11204, NCGC00016160-01, NCGC00016160-03, NCGC00016160-04, NCGC00016160-05, NCGC00021145-11, NCGC00094068-01, NCGC00094068-02, NCGC00094068-03, NCGC00261405-01, O287, SAM001247061, LS-147408, EU-0100720, FT-0653022, SW196603-4, VU0239541-8, D00794, 833L643, C-54162, SR-01000002971-2, SR-01000002971-6, SR-01000002971-9, 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine, Succinate, Loxapine succinate, United States Pharmacopeia (USP) Reference Standard, (E)-2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine succinate, 2-Chloro-11-(4-methyl-1- piperazinyl)-dibenz[b,f][1,4]- oxazepine succinate, butanedioic acid; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine, Loxitane, loxapine, Oxilapine, Adasuve, Loxapinesuccinatesalt, C18H18ClN3O, C18H18ClN3O.C4H6O4, CID71399, AR-1E0046, CS-O-30637, CL-62362, C18-H18-Cl-N3-O.C4-H6-O4, B1783, L-106, S-805, Lidocaine succinate, 98%, a 5-HT inhibitor; dopamine receptor - 1G 1g, 28664-37-1, Succinic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1), Succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz[b,f][1,4]oxazepine (1:1),

Complexity	542
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	2
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Exact Mass	445.14g/mol
Formal Charge	0
Heavy Atom Count	31
Hydrogen Bond Acceptor Count	7
Hydrogen Bond Donor Count	2
Isotope Atom Count	0
Molecular Weight	445.9g/mol
Monoisotopic Mass	445.14g/mol
Rotatable Bond Count	4
Topological Polar Surface Area	103A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class	6.1
Hazard statements	H302
Packing Group	Ⅱ
Precautionary statements	P280-P305+P351+P338
UN Code	UN 2811

Certificate of Analysis

Lot Number